Tats, you are right. GLP-1's will outsell Vascepa. By a massive margin. But so will statins. And so will plenty of other drugs.
However, this does not prevent Vascepa from being successful. They are not mutually exclusive. They are totally different drugs.
The biggest challenge facing the commercial development of Vascepa is convincing people that it works, in the face of a lack of clearly defined evidence. That may never happen (to a great enough degree), but it's what is necessary if Vascepa is to ever reach its full potential.
Market Data 
Markets 
AI
